The mission of the UF Health Cancer Center Clinical Trials Office (CTO) is to help deliver new and promising cancer treatments that improve the lives of our patients at the UF Health Cancer Center. The CTO provides support to our clinical investigators for the development and implementation of cancer clinical trials — facilitating the conduct of high-quality clinical research while adhering to the highest ethical standards and maintaining compliance with all governing bodies. This program will continue to undergo significant expansion over the next few years, as part of the initiative to become a National Cancer Institute-designated cancer center.
Currently, our clinical research program consists of the CTO and 11 disease-specific working groups (e.g., thoracic, GI, GU, neuro-oncology, hematologic malignancies). It also supports an Experimental Therapeutics Incubator for early-phase clinical trials that may have patient eligibility across several cancer types. Additionally, the Clinical Trials Office provides clinical trial support for outside institutions with affiliations through UF Health, the university’s academic health center.
The UF Health Cancer Center has been selected as one of 12 initial clinical trial sites participating in Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
An initiative of the national nonprofit organization Pancreatic Cancer Action Network, Precision Promise is intended to dramatically accelerate the clinical trial process to bring promising therapies to patients faster.
“Being an inaugural member of the Precision Promise clinical trial consortium ensures that our patients have access to some of the most cutting-edge and innovative therapies available in the world for pancreatic cancer,” said Thomas George, M.D., the study’s principal investigator at UF and medical director of the GI Oncology Program. “The tools to help our patients fight pancreatic cancer and advance the field are now at our ready.”